Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers.
Miletić D, Kraljević M, Sokolović E, Soče M, Milović-Kovačević M, Bobić S, Cerić T, Pleština S, Bešlija S, Marijanović I. Miletić D, et al. Among authors: ceric t. Med Sci Monit. 2023 Jun 2;29:e940356. doi: 10.12659/MSM.940356. Med Sci Monit. 2023. PMID: 37264567 Free PMC article.
Long-term outcome of GIST patients treated with delayed imatinib therapy.
Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, Vranic S, Kopric D, Iljazovic E, Todorovic Barbuscia J, Kozaric M, Ibisevic N, Keskic L, Kurtovic S. Kurtovic-Kozaric A, et al. Among authors: ceric t. Eur J Cancer. 2017 Jun;78:118-121. doi: 10.1016/j.ejca.2017.03.024. Epub 2017 Apr 21. Eur J Cancer. 2017. PMID: 28437709 No abstract available.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Letter to the Editor/Response.
Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, Vranic S. Imamovic D, et al. Among authors: ceric t. Breast J. 2019 May;25(3):569. doi: 10.1111/tbj.13284. Epub 2019 Apr 13. Breast J. 2019. PMID: 30980590 No abstract available.
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, Vranić S, Mustedanagić-Mujanović J, Skenderi F, Rakita I, Guzijan A, Koprić D, Humačkić A, Trokić D, Alidžanović J, Efendić A, Šišić I, Drljević H, Bešlagić V, Babić B, Pašić A, Ramić A, Mikić D, Guzin Z, Karan D, Buhovac T, Miletić D, Šečić S, Đozić Šahmić A, Mujbegović L, Kubura A, Burina M, Lalović N, Dukić N, Vladičić Mašić J, Ćuk M, Stanušić R. Bešlija S, et al. Among authors: ceric t. Bosn J Basic Med Sci. 2021 Apr 1;21(2):120-135. doi: 10.17305/bjbms.2020.4846. Bosn J Basic Med Sci. 2021. PMID: 32415816 Free PMC article.
Use of the Depression, Anxiety and Stress Scale (DASS-21) Questionnaire to Assess Levels of Depression, Anxiety, and Stress in Healthcare and Administrative Staff in 5 Oncology Institutions in Bosnia and Herzegovina During the 2020 COVID-19 Pandemic.
Marijanović I, Kraljević M, Buhovac T, Cerić T, Mekić Abazović A, Alidžanović J, Gojković Z, Sokolović E. Marijanović I, et al. Among authors: ceric t. Med Sci Monit. 2021 Apr 19;27:e930812. doi: 10.12659/MSM.930812. Med Sci Monit. 2021. PMID: 33867520 Free PMC article.
26 results